Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River (CRL) Launches Viral Vector Tech Transfer Program
11:46am, Friday, 31'st May 2024
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
Charles River Laboratories: Fair Valuation Against Fundamentals
04:44am, Friday, 31'st May 2024
The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratorie
Reasons to Hold Charles River (CRL) in Your Portfolio Now
08:21am, Thursday, 30'th May 2024
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
08:00am, Thursday, 30'th May 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer fr
Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software
04:12am, Tuesday, 28'th May 2024
LONDON--(BUSINESS WIRE)-- #lifesciences--Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River's sample management capabilities.
Charles River (CRL) Banks on RMS Growth Amid Competition
12:41pm, Friday, 24'th May 2024
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
01:16pm, Monday, 13'th May 2024
Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
10:46am, Monday, 13'th May 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
01:26pm, Thursday, 09'th May 2024
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 09'th May 2024
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
The 7 Best Growth Stocks to Buy in May 2024
06:00am, Wednesday, 08'th May 2024
It's been a tremendous year for growth stocks. New technologies and increasing consumer adoption in fields such a semiconductors, electric vehicles, and generative AI have led to tremendous gains for
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:22am, Monday, 06'th May 2024
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
08:00am, Thursday, 02'nd May 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vec
ICLR vs. CRL: Which Stock Is the Better Value Option?
12:45pm, Monday, 29'th Apr 2024
Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors wi
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
01:50pm, Wednesday, 24'th Apr 2024
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
